JMI Laboratories, North Liberty, Iowa, USA.
Microb Drug Resist. 2022 Sep;28(9):935-940. doi: 10.1089/mdr.2022.0046. Epub 2022 Aug 17.
We evaluated the activity of ceftaroline against clinical isolates of ceftriaxone-nonsusceptible from United States medical centers. isolates ( = 21,750) were consecutively collected from 201 medical centers in 2008-2020 and tested for susceptibility by broth microdilution method. Among these isolates, 1,419 (6.5%) were ceftriaxone-nonsusceptible (ceftriaxone minimum inhibitory concentration [MIC], ≥2 mg/L). Other resistant subgroups analyzed included multidrug-resistant (MDR; nonsusceptibility to ≥3 classes of agents; = 4,454) and extensively drug-resistant (XDR; nonsusceptibility to ≥5 classes; = 1,708) isolates. Ceftriaxone susceptibility increased from 89.0% (2008-2011) to 98.1% (2018-2020). Ceftaroline was active against 99.9% of ceftriaxone-nonsusceptible isolates (MIC, 0.25/0.25 mg/L) and retained potent activity against MDR ( = 4,454; MIC, 0.12/0.25 mg/L; >99.9% susceptible) and XDR ( = 1,708; MIC, 0.25/0.25 mg/L; 100.0% susceptible) isolates. Only one isolate had a ceftaroline MIC ≥0.5 mg/L. In summary, ceftaroline demonstrated potent and consistent activity over time (2008-2020) against a large collection of from U.S. medical centers, including ceftriaxone-nonsusceptible, MDR, and XDR isolates.
我们评估了头孢洛林对来自美国医疗中心的头孢曲松不敏感的临床分离株的活性。 从 2008 年至 2020 年，连续从 201 个医疗中心收集了 21750 株分离株，并通过肉汤微量稀释法检测其药敏性。在这些分离株中，有 1419 株（6.5%）对头孢曲松不敏感（头孢曲松最小抑菌浓度 [MIC]，≥2mg/L）。分析的其他耐药亚组包括多药耐药（MDR；对≥3 类药物不敏感； = 4454）和广泛耐药（XDR；对≥5 类药物不敏感； = 1708）分离株。头孢曲松的敏感性从 89.0%（2008-2011 年）增加到 98.1%（2018-2020 年）。头孢洛林对 99.9%的头孢曲松不敏感分离株（MIC，0.25/0.25mg/L）具有活性，并对 MDR（ = 4454；MIC，0.12/0.25mg/L；>99.9%敏感）和 XDR（ = 1708；MIC，0.25/0.25mg/L；100.0%敏感）分离株保持强大的活性。只有 1 株分离株的头孢洛林 MIC≥0.5mg/L。总之，头孢洛林在 2008 年至 2020 年期间对来自美国医疗中心的大量 分离株（包括头孢曲松不敏感、MDR 和 XDR 分离株）表现出强大而一致的活性。
